ECSP088902A - Derivados de pirazolo[3,4-d]-pirimidina utiles para tratar trastornos respiratorios - Google Patents

Derivados de pirazolo[3,4-d]-pirimidina utiles para tratar trastornos respiratorios

Info

Publication number
ECSP088902A
ECSP088902A EC2008008902A ECSP088902A ECSP088902A EC SP088902 A ECSP088902 A EC SP088902A EC 2008008902 A EC2008008902 A EC 2008008902A EC SP088902 A ECSP088902 A EC SP088902A EC SP088902 A ECSP088902 A EC SP088902A
Authority
EC
Ecuador
Prior art keywords
pirazolo
pirimidine
derivatives
useful
respiratory disorders
Prior art date
Application number
EC2008008902A
Other languages
English (en)
Inventor
Ian Bruce
Graham Charles Bloomfield
Judy Hayler
Brian Cox
Lee Edwards
Catherine Howsham
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36687588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088902(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP088902A publication Critical patent/ECSP088902A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a un compuesto de la Fórmula (I):o una sal farmacéuticamente aceptable o un solvato del mismo, en donde R1-R3 e Y se definen en la descripción, y a su uso en el tratamiento de trastornos en donde esté implicada la cinasa pi3.
EC2008008902A 2006-05-23 2008-11-21 Derivados de pirazolo[3,4-d]-pirimidina utiles para tratar trastornos respiratorios ECSP088902A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0610242.0A GB0610242D0 (en) 2006-05-23 2006-05-23 Organic compounds

Publications (1)

Publication Number Publication Date
ECSP088902A true ECSP088902A (es) 2008-12-30

Family

ID=36687588

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008902A ECSP088902A (es) 2006-05-23 2008-11-21 Derivados de pirazolo[3,4-d]-pirimidina utiles para tratar trastornos respiratorios

Country Status (24)

Country Link
US (5) US20090131457A1 (es)
EP (1) EP2026811A1 (es)
JP (1) JP2009537580A (es)
KR (1) KR101106853B1 (es)
CN (1) CN101443013A (es)
AR (2) AR061057A1 (es)
AU (1) AU2007253615B2 (es)
BR (1) BRPI0712022A2 (es)
CA (1) CA2650661A1 (es)
CL (1) CL2007001455A1 (es)
CR (1) CR10419A (es)
EC (1) ECSP088902A (es)
GB (1) GB0610242D0 (es)
GT (1) GT200800256A (es)
IL (1) IL195017A0 (es)
MA (1) MA30433B1 (es)
MX (1) MX2008014835A (es)
NO (1) NO20084997L (es)
PE (1) PE20080315A1 (es)
RU (1) RU2008150619A (es)
TN (1) TNSN08478A1 (es)
TW (1) TW200806665A (es)
WO (1) WO2007134828A1 (es)
ZA (1) ZA200809097B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
KR101499783B1 (ko) 2006-04-04 2015-03-09 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
WO2009013348A2 (en) * 2007-07-26 2009-01-29 Novartis Ag Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
ES2401557T3 (es) 2007-08-02 2013-04-22 Amgen, Inc Moduladores de Pl3 cinasas y métodos de uso
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
CL2008003798A1 (es) 2007-12-19 2009-10-09 Amgen Inc Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
AU2009204483B2 (en) 2008-01-04 2014-03-13 Intellikine, Llc Certain chemical entities, compositions and methods
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
EP2111861A1 (en) * 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
EP2307400B1 (en) 2008-05-30 2014-04-23 Amgen, Inc Inhibitors of pi3 kinase
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
US8220787B2 (en) * 2008-09-19 2012-07-17 Panasonic Corporation Part mounting device
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
WO2010045542A2 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
CA2756871A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted heterocyclic compounds
WO2010129816A2 (en) 2009-05-07 2010-11-11 Intellikine, Inc. Heterocyclic compounds and uses thereof
EP2488511A1 (en) * 2009-10-02 2012-08-22 Vertex Pharmaceuticals Incorporated Pyrazole inhibitors of phosphatidylinositol 3-kinase
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
US9290499B2 (en) 2010-05-19 2016-03-22 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20180080358A (ko) 2011-01-10 2018-07-11 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀린온 및 이의 고체 형태의 제조 방법
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
EP2734530A1 (en) 2011-07-19 2014-05-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
AU2011376717A1 (en) 2011-09-14 2014-03-20 Proximagen Limited New enzyme inhibitor compounds
GB201115853D0 (en) 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
WO2013052417A1 (en) 2011-10-03 2013-04-11 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2014145121A (ru) 2012-05-22 2016-07-10 Зэ Юниверсити Оф Норд Каролина Эт Чапел Хилл Пиримидиновые соединения для лечения злокачественной опухоли
KR20160027219A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014052669A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
EP2909211A4 (en) 2012-10-17 2016-06-22 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
IL291945B2 (en) 2012-11-01 2025-11-01 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
EP2925752A4 (en) 2012-11-27 2016-06-01 Univ North Carolina PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014153509A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP4066834A1 (en) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015157122A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrazolopyrimidine compounds
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CZ308056B6 (cs) * 2015-07-20 2019-11-27 Ustav Experimentalni Botaniky Av Cr V V I 5-Substituované-7-[4-(substituované)benzyl]amino-3-isopropylpyrazolo[4,3-d]pyrimidiny, jejich použití jako antirevmatika, a farmaceutické přípravky
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
SMT202200348T1 (it) 2016-04-15 2022-11-18 Cancer Research Tech Ltd Composti eterociclici come inibitori della chinasi ret
IL297192A (en) 2016-04-15 2022-12-01 Cancer Research Tech Ltd Heterocyclic compounds as ret kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
AU2020412779A1 (en) * 2019-12-23 2022-06-23 Sanford Burnham Prebys Medical Discovery Institute Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) modulators and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR205429A1 (es) * 1971-04-27 1976-05-07 Ciba Geigy Ag Procedimiento para la elaboracion de nuevos derivados de 4-amino - 3-(5-nitro- 2 -furil)-1-metil - 1h - pirazol-(3,4-ol)-pirimidina
AR204665A1 (es) * 1974-05-13 1976-02-20 Lilly Co Eli Procedimiento para preparar compuestos de 3-(5-nitroimidazol-2-il)pirazolo(3,4d)pirimidina
US4044130A (en) * 1974-07-03 1977-08-23 Ciba-Geigy Corporation Compositions for the control of microorganisms
JPS5195094A (en) * 1975-01-31 1976-08-20 * ***** ****so*shi***** *o*u****** ********ne***u**** *** *** ****ne*** *************te***ku**
GB0013674D0 (en) * 1999-06-08 2000-07-26 Lorantis Ltd Therapeutic use
IL148718A0 (en) * 1999-09-17 2002-09-12 Abbott Gmbh & Co Kg Pyrazolopyrimidines as therapeutic agents
MXPA02010618A (es) * 2000-04-25 2004-05-05 Icos Corp Inhibidores de fosfatidilinositol 3-quinasa delta.
WO2003029209A2 (en) * 2001-10-02 2003-04-10 Smithkline Beecham Corporation Chemical compounds
AU2003225933A1 (en) * 2002-03-22 2003-10-13 Cellular Genomics, Inc. AN IMPROVED FORMULATION OF CERTAIN PYRAZOLO(3,4-d) PYRIMIDINES AS KINASE MODULATORS
US7429596B2 (en) * 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
JP2007520559A (ja) * 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
US9512125B2 (en) * 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
JP2009531443A (ja) * 2006-03-29 2009-09-03 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド α−シヌクレイン毒性の抑制

Also Published As

Publication number Publication date
US20140235632A1 (en) 2014-08-21
KR20090008392A (ko) 2009-01-21
CL2007001455A1 (es) 2008-05-16
AR110051A2 (es) 2019-02-20
NO20084997L (no) 2008-12-22
CN101443013A (zh) 2009-05-27
BRPI0712022A2 (pt) 2011-12-27
JP2009537580A (ja) 2009-10-29
EP2026811A1 (en) 2009-02-25
RU2008150619A (ru) 2010-06-27
WO2007134828A1 (en) 2007-11-29
IL195017A0 (en) 2009-08-03
CA2650661A1 (en) 2007-11-29
US20160303132A1 (en) 2016-10-20
MA30433B1 (fr) 2009-05-04
PE20080315A1 (es) 2008-06-11
TW200806665A (en) 2008-02-01
US20180125849A1 (en) 2018-05-10
GT200800256A (es) 2009-05-28
TNSN08478A1 (en) 2010-04-14
KR101106853B1 (ko) 2012-01-19
ZA200809097B (en) 2009-11-25
US20090131457A1 (en) 2009-05-21
AU2007253615B2 (en) 2011-06-23
MX2008014835A (es) 2008-12-01
US8901134B2 (en) 2014-12-02
AU2007253615A1 (en) 2007-11-29
US20140051698A1 (en) 2014-02-20
GB0610242D0 (en) 2006-07-05
CR10419A (es) 2011-07-19
AR061057A1 (es) 2008-07-30

Similar Documents

Publication Publication Date Title
ECSP088902A (es) Derivados de pirazolo[3,4-d]-pirimidina utiles para tratar trastornos respiratorios
MX2009001660A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis.
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
CR20140392A (es) Dihidropirazolonas sustituidas
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
UY30411A1 (es) Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
EA201170249A1 (ru) 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
AR062401A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
CO6290670A2 (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
BRPI0715698B8 (pt) produto, composição farmacêutica que o contém e uso de composto
AR062390A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
WO2007046867A3 (en) Piperidine derivatives and their uses as therapeutic agents
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
ATE492534T1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
ATE495159T1 (de) Diaminocyclohexan- und diaminocyclopentanderivate
TW200806321A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
EA200702282A1 (ru) Комбинация феррохина и производного артемизинина для лечения малярии